The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Arrowhead Pharmaceuticals announced positive Phase 3 topline results from its SHASTA-3 and SHASTA-4 studies of plozasiran, which successfully met the primary endpoint of reducing triglycerides in patients with severe hypertriglyceridemia. Following this, the CHMP issued a positive opinion recommending marketing authorization for Ubeslo and Evlarco in Europe. On July 25, NewAmsterdam Pharma and Menarini Group received this formal recommendation to advance the commercialization of these treatments.